

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA)

Rating: Buy

Price Target: \$3.00

Share Price: \$1.38

Karen Sterling, PhD, CFA
ksterling@kingswoodus.com

November 17, 2025

Company Data

Average Daily Volume (M)	3.05
52-Week Range	0.73-2.45
Shares Outstanding (M)	41.88
Market Cap (M)	57.79
Enterprise Value (M)	50.25
Total Cash (M), mrq	2.64
Total Debt (M)	0
Total Debt to Cap	0

Estimates

	FYE: Dec	2024A	2025E	2026E
EPS	Q1	(0.09)	(0.11)A	
	Q2	(0.11)	(0.09)A	
	Q3	(0.14)	(1.18)	
	Q4	(0.18)	(0.04)	
	FY	(0.51)	(1.17)	(0.18)
P/E		NM	NM	NM
Rev	Q1	0.0	0.0	0.0
	Q2	0.0	0.0	0.0
	Q3	0.0	0.0	0.0
	Q4	0.0	0.0	0.0
	FY	0.0	0.0	0.0
EV/Sales		N/A	N/A	N/A

One-Year Performance Chart



As of November 14, 2025. Source: E*Trade.

MIRA Pharmaceuticals Reports Q3 2025 Results

Q3 FY 2025 earnings beat our projections; short-term liquidity improved

Q3 Financial Results Summary

MIRA Pharmaceuticals, a pharmaceutical development company advancing a pipeline of one clinical-stage and two preclinical-stage assets focused on neuroscience and metabolic-behavioral applications, reported financial results for the quarter ended September 30, 2025. Revenue was \$0, on par with our estimate. Q3 2025 net loss was \$1.14 million, or (\$0.06) per share on 19.27 million weighted average common shares outstanding, beating our (\$0.08) EPS estimate due to lower than expected operating costs. Net loss attributable to common shareholders was \$22.69 million, or (\$1.18) per share due to a deemed dividend of \$21.56 million associated with the acquisition of SKNY Pharmaceuticals.

We note that stock-based compensation expense for the nine months ended September 30, 2025 was \$1.76 million, constituting 51% of total G&A expense of \$3.45 million. Common shares outstanding increased from 16.56 million on December 31, 2024, to 41.88 million on November 11, 2025, representing 153% dilution year to date.

MIRA's cash position declined from \$2.83 million on December 31, 2024 to \$2.64 million on September 30, 2025. The Company did not have sufficient cash and cash equivalents on September 30, 2025 to support operations for at least the next 12 months, but raised an additional \$3.7 million from its ATM facility, and received an additional \$0.59 million in net proceeds from stock option exercises in October 2025.

Management plans to secure additional capital through public equity offerings under the Company's ATM agreement and strategic transactions, including potential alliances and drug product collaborations; however, none of these alternatives are committed at this time. As of September 30, 2025, MIRA has sold 4,133,402 shares in ATM transactions, generating net proceeds of \$6.7 million. The maximum amount eligible to be sold under the ATM agreement is \$75 million.

We expect ATM transactions to be the main source of liquidity for MIRA going forward, which would further dilute current shareholders. Other potential sources of dilution, as of September 30, 2025, include 5.35 million of outstanding stock options and warrants, which have a weighted average exercise price per share of \$1.19 and \$3.88, respectively.

The Company used \$3.5 million of cash in operations during the first nine months of 2025. Currently available cash is expected to support operations through Q3 2026. 2026 liquidity needs will be determined by the operational expenditure incurred from the advancement of MIRA's product candidates into and through clinical trials.

The Company's current ratio increased from 2.8x at the end of Q2 2025 to 90.5x on September 30, due to an increase in current assets from \$0.83 million to \$7.60 million, coupled with a decrease in current liabilities from \$0.30 million to \$0.08 million.

Commercial and Clinical Highlights

Acquisition of SKNY Pharmaceuticals

MIRA's acquisition of SKNY Pharmaceuticals, Inc., a privately-held Delaware corporation with a preclinical-stage oral drug candidate, SKNY-1, targeting weight loss and smoking cessation, via a stock exchange transaction, closed on September 29, 2025, and established SKNY Pharmaceuticals as a wholly owned subsidiary of MIRA. The transaction brought the Company back into compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of \$2.5 million in stockholders' equity. Total stockholder's equity as of September 30, 2025, was \$7.5 million.

The transaction was recorded as an asset acquisition at acquired cost basis with two assets acquired: (i) a license agreement for SKNY-1 (with SKNY Pharmaceuticals as licensee and MIRALOGX, a related party, as licensor) and (ii) 3,521,127 shares of common stock of Telomir Pharmaceuticals, Inc. (TELO), a publicly traded preclinical-stage biotechnology company, which is a related party to MIRA due to certain common ownership, officers, and directors. The 3,521,127 shares of TELO common stock were contributed to MIRA on behalf of SKNY by SKNY's largest shareholder and were recorded on MIRA's September 3, 2025 balance sheet as a short-term equity investment valued at \$4,718,310 based on the TELO closing price on September 29, 2025 of \$1.34 per share.

Also on September 29, 2025, MIRA issued 19,755,738 new shares of MIRA common stock to SKNY shareholders. The common shares were valued at \$26,275,132 based on the MIRA September 29 closing price of \$1.33 per share. The excess fair value of the MIRA common shares issued over the \$4,718,310

net assets received in SKNY of \$21,556,821 has been reflected as a deemed dividend with a charge to additional paid-in capital of \$21,556,821. The net increase to equity of the common shares was \$4,718,311.

In the SKNY asset acquisition, MIRA Pharmaceuticals gained the rights to commercialize SKNY-1 in the U.S., Canada, and Mexico. Pursuant to the terms of the SKNY license, MIRA will be obligated to pay MIRALOGX a royalty of 8% of net sales, with a minimum annual royalty of \$250,000. Unless earlier terminated, the SKNY license agreement will continue in effect until the last to expire of the patent rights licensed pursuant to the SKNY license.

Ketamir-2 Developments

In clinical news, MIRA's ongoing Phase 1 clinical trial of Ketamir-2, being conducted in healthy volunteers in Israel, completed the single ascending dose portion on August 19, 2025, and commenced the multiple ascending dose portion of the trial on October 24, 2025. MIRA anticipates beginning a U.S.-based Phase 2a clinical trial in neuropathic pain, its lead indication for Ketamir-2, by year-end, following FDA clearance of the Company's Investigational New Drug (IND) application for Ketamir-2 in the U.S. on July 28, 2025.

On September 16, 2025, MIRA announced that its oral Ketamir-2 restored normalized behavior in stressed animals within a validated model of post-traumatic stress disorder (PTSD), opening up a potential follow-on indication and market expansion opportunity.

Based on currently available data, we believe Ketamir-2 may have potential as a safe and effective treatment for chronic pain and expect development of the asset to proceed in partnership with academic medical centers and/or pharmaceutical companies. We also expect to see IND filings for MIRA-55 and SKNY-1 during 2026.

While clinical and preclinical data generated to date has been promising, we remain concerned about the pace of shareholder dilution, which is approaching 200% since MIRA's August 2023 IPO, continuing to put downward pressure on MIRA's stock. On the upside, we believe that positive Phase 2 results for Ketamir-2 in neuropathic pain could represent a significant value inflection point for the Company, which leads us to reiterate our BUY rating on the stock.

Company Description

MIRA Pharmaceuticals, Inc. is a clinical development-stage life sciences company with three neuroscience programs targeting a broad range of neurologic diseases and neuropsychiatric disorders:

1. Ketamir-2, a novel oral ketamine analog, is in Phase 1 dosing trials and being developed to address various neuropathic pain indications. It may also have the potential to deliver ultra-rapid antidepressant effects for patients suffering from major depressive disorder (MDD) and PTSD.
2. SKNY-1, a novel oral modulator of CB1, CB2, and MAO-B pathways to address energy storage, lipid metabolism, appetite, cravings, and reward-seeking behavior, is in preclinical development for obesity and nicotine addiction.
3. MIRA-55, a novel oral synthetic tetrahydrocannabinol (THC) pharmaceutical, is in IND-enabling studies to treat inflammatory and nociceptive pain.

Both Ketamir-2 and MIRA-55 are classified as unscheduled drugs by the DEA and are therefore not considered controlled substances or listed chemicals.

MIRA Pharmaceuticals was incorporated in September 2020 and is a virtual company with no physical office space or corporate headquarters. The Company completed its initial public offering on August 3rd, 2023, and its common stock began trading on the Nasdaq Capital Market under the symbol “MIRA.”

MIRA Pharmaceuticals, Inc. Income Statement 2024-2026

MIRA Pharmaceuticals, Inc. (MIRA)	FY 24 A	3/31/25 A	6/30/25 A	9/30/25 A	12/31/25	FY 25	FY 26
Revenues, net of royalties	-	-	-	-	-	-	-
Operating costs:							
G&A	4,712,754	1,490,796	1,049,903	904,346	1,085,215	4,530,260	4,983,286
R&D	3,305,575	314,404	496,197	412,639	808,267	2,031,507	3,047,261
Total operating costs	8,018,329	1,805,200	1,546,100	1,316,985	1,893,482	6,561,767	8,030,547
Interest income, net	165,670	21,421	8,495	15,697	30,000	75,613	100,000
Unrealized gain on short-term investments				176,056			
Other income/(expense)			(107)	(12,441)			
Taxes	-	-	-	-	-	-	-
Net loss	(7,852,659)	(1,783,779)	(1,537,712)	(1,137,673)	(1,863,482)	(6,322,646)	(7,930,547)
Deemed dividend				(21,556,821)			
Net loss attributable to common shareholders	(7,852,659)	(1,783,779)	(1,537,712)	(22,694,494)	(1,863,482)	(27,879,467)	(7,930,547)
Basic and diluted loss per share	(\$0.51)	(\$0.11)	(\$0.09)	(\$1.18)	(\$0.04)	(\$1.17)	(\$0.18)
Weighted average common shares outstanding	15,444,149	16,645,119	16,986,488	19,274,947	42,500,000	23,851,639	45,000,000

Sources: Company filings, Kingswood estimates.

Risks to Our Price Target

- **High Failure Rate in Drug Development.** Conclusions based on preclinical data or early clinical trials may prove inaccurate and are not necessarily predictive of future results in later stage clinical trials. There is a high rate of failure for drug candidates proceeding through clinical trials. MIRA Pharmaceuticals' long-term viability depends on the success of its product candidates, some or all of which may fail to receive regulatory approval.
- **Future Market Traction Remains Uncertain.** Even upon receiving FDA marketing approval, MIRA's product candidates may fail to achieve the degree of market penetration required for commercial success. Reimbursement by third-party payors will be instrumental in gaining market traction.
- **Competition From Companies with Greater Resources.** The emerging market for synthetic cannabinoids as well as development and commercialization of drugs is and will remain competitive. For some of MIRA's areas of therapeutic interest, various treatment options are already available, and new treatments are under development by competitors with greater financial and technical resources than MIRA's. Achieving market traction will require superior safety and efficacy profiles compared to existing options, at competitive price points.
- **Outsourcing Clinical Development and Manufacturing Creates Vulnerabilities.** Any problems in MIRA Pharmaceuticals' anticipated outsourcing of clinical trials and manufacturing processes and capabilities could have a material adverse effect on its business and financial condition.
- **No Patent Protection Exists for MIRA-55.** MIRA Pharmaceuticals has no issued patents relating to MIRA-55, and its patent application for MIRA-55 may not result in the issuance of such patents. This would significantly impact MIRA-55's potential competitive position and likely result in diminished market share, price levels, and third-party reimbursement.
- **Strength of Intellectual Property Remains Untested.** If the scope of MIRA's intellectual property portfolio is not broad enough, competitors could design comparable products around MIRA's technology or patent rights and hamper its ability to successfully commercialize its products. In addition, patent protection for naturally occurring compounds is difficult to obtain, defend, and enforce. Patent litigation is expensive and would siphon off limited resources.
- **Uncertain Ability to Continue as a Going Concern.** Because MIRA Pharmaceuticals is not currently generating revenue and operates at a loss, the Company is dependent on the continued availability of additional financing to continue business operations. Clinical trials are expensive, time-consuming, uncertain, and susceptible to change, delay, or termination. The FDA regulatory approval process is lengthy and inherently unpredictable. MIRA's current cash reserves should fund operations through Q4 2025, but there is no assurance that additional financing will be available on reasonable terms.

- **Ability to Maintain Nasdaq Listing Requirements in Question.** MIRA stock has seen a sharp decline from its IPO price of \$7.00 to its current price in the \$1.00-\$2.00 range. In light of the need to raise additional capital, if MIRA fails to remain in compliance with the Nasdaq requirements the Company's shares could be delisted. As a result, liquidity would drop, MIRA's ability to raise future rounds of external capital via equity or debt financing would be impaired, the terms and conditions of future financings could be punitive, and current shareholders might experience significant dilution.

DISCLOSURES

Analyst Certification

The Research Analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst’s personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report.

I, Karen Sterling, certify that (1) the views expressed in this report accurately reflect my own views about any and all of the subject companies and securities; and (2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by me in this report.

Explanation of Research Ratings (As of January 1, 2024), Designations and Analyst(s) Coverage Universe:

Kingswood Capital Partners, LLC uses the following rating system:

Buy - Buy-rated stocks are expected to have a total return of at least 15% over the following 12 months and are the most attractive stocks in the sector coverage area.

Hold - We believe this stock will perform in line with the average return of others in its industry over the following 12 months.

Sell - Sell-rated stocks are expected to have a negative total return of at least 15% over the following 12 months and are the least attractive stocks in the sector coverage area.

Not Rated (NR) - Kingswood Capital Partners, LLC DOES NOT cover this stock and therefore DOES NOT have forecasts, projections, target price and recommendation on the shares of this company.


Company-Specific Disclosures

Distribution of Ratings Kingswood Capital Partners, LLC				
Investment Banking Services/Past 12 Months				
Rating	Count	Percent	Count	Percent
BUY	9	81.81	2	22.22
HOLD	1	9.09	0	0.00
SELL	0	0.00	0	0.00
NOT RATED	1	9.09	1	100.00

As of July 2025.

Kingswood Capital Partners is not currently engaged by MIRA Pharmaceuticals to provide investment banking or advisory services, nor has Kingswood received compensation from MIRA during the past 12 months.

MIRA Pharmaceuticals Rating History



As of November 14, 2025. Source: E*Trade.

Other Disclosures

This report has been prepared by Kingswood Capital Partners, LLC. It does not constitute an offer or solicitation of any transaction in any securities referred to herein. Any recommendation contained in this report may not be suitable for all investors. Although the information contained herein has been obtained from recognized services, issuer reports or communications, or other services and sources believed to be reliable, its accuracy or completeness cannot be guaranteed. This report may contain links to third-party websites, and Kingswood Capital Partners, LLC is not responsible for their content or any linked content contained therein. Such content is not part of this report and is not incorporated by reference into this report. The inclusion of a link in this report does not imply any endorsement by or affiliation with Kingswood Capital Partners, LLC; access to these links is at your own risk. Any opinions, estimates or projections expressed herein may assume some economic, industry and political considerations and constitute current opinions, at the time of issuance, that are subject to change. Any quoted price is as of the last trading session unless otherwise noted. Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. Investors in such securities and instruments, including ADRs, effectively assume currency risk. This information is being furnished to you for informational purposes only, and on the condition that it will not form a primary basis for any investment decision. Investors must make their own determination of the appropriateness of an investment in any securities referred to herein based on the applicable legal, tax and accounting considerations and their own investment strategies. By virtue of this publication, neither the Firm nor any of its employees shall be responsible for any investment decision.